Intrexon Corporation (NYSE:XON) Analyst Rating Consensus

Intrexon Corporation (NYSE:XON) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.86 by 7 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON). According to the latest information available, the shares are now rated Market Outperform by the analysts at the agency. The rating by the firm was issued on May 3, 2016.

Intrexon Corporation (NYSE:XON) should head towards $48.13 per share according to 8 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $29 per share. The higher price estimate target is at $65 according to the Analysts.

Intrexon Corporation (NYSE:XON) witnessed a decline in the market cap on Tuesday as its shares dropped 1.35% or 0.34 points. After the session commenced at $25.37, the stock reached the higher end at $25.6199 while it hit a low of $24.435. With the volume soaring to 1,195,154 shares, the last trade was called at $24.78. The company has a 52-week high of $69.45. The company has a market cap of $2,928 million and there are 118,164,614 shares in outstanding. The 52-week low of the share price is $18.5201.

Intrexon Corporation has lost 0.28% in the last five trading days and dropped 11.66% in the last 4 weeks. Intrexon Corporation has dropped 34.44% during the last 3-month period . Year-to-Date the stock performance stands at -17.81%.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *